Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | TYK2 | P29597 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 6/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCND2 | P30279 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167422 | 0.90 | JAK1 (0.48) | CCNB2CDK1CCNB1CCNB3JAK1 | |
| SCHEMBL1168692 | 0.89 | JAK2 (0.57) | CCNB2CDK1CCNB1CCNB3JAK1 | |
| SCHEMBL1167655 | 0.87 | JAK1 (0.46) | CCNB2CDK1CCNB1CCNB3JAK1 | |
| SCHEMBL1167428 | 0.85 | AXL (0.56) | JAK1TYK2JAK2JAK3INSR | |
| SCHEMBL1167441 | 0.85 | JAK1 (0.44) | CCNB2CDK1CCNB1CCNB3JAK1 | |
| SCHEMBL1167703 | 0.85 | JAK1 (0.47) | CCNB2CDK1CCNB1CCNB3JAK1 | |
| SCHEMBL1167481 | 0.85 | BACE1 (0.56) | INSRAXL | |
| SCHEMBL1167340 | 0.85 | BACE1 (0.56) | INSRAXL | |
| SCHEMBL1167955 | 0.85 | AXL (0.51) | JAK2INSRAXL | |
| SCHEMBL1167954 | 0.83 | AXL (0.58) | CDK1JAK2JAK3INSRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| US-8389557-B2 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, FLT3 | CCNB2 1915/4885CDK1 202/4885CCNB1 2575/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | CCNB2 2510/4885CDK1 307/4885CCNB1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.